Terms ending in 2042
Every in-force patent on Gilead Sciences, Inc.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,613,546 | Substituted Pyridotriazine Compounds and Uses Thereof In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 11,897,892 | Substituted Pyridotriazine Compounds and Uses Thereof In force · Low confidence | Gilead Sciences, Inc. | In force | Low confidence | |
| US 12,187,734 | Substituted Pyridotriazine Compounds and Uses Thereof In force · Low confidence | Gilead Sciences, Inc. | In force | Low confidence | |
| US 12,331,125 | Anti-cMet Antibody-Drug Conjugates and Uses Thereof In force · Medium confidence | Gilead Sciences, Inc. | In force | Medium confidence | |
| US 12,030,903 | Antiviral Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 12,102,677 | Methods of Identifying HIV Patients Sensitive to Therapy with GP120 V3 Glycan-Directed Antibodies In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 12,091,404 | GLP-1R Modulating Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 12,180,197 | GLP-1R Modulating Compounds In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| US 12,240,862 | Inhibitors of Peptidylarginine Deiminases In force · Medium confidence | Gilead Sciences, Inc. | In force | Medium confidence | |
| US 12,410,160 | KHK Inhibitors In force · High confidence | Gilead Sciences, Inc. | In force | High confidence | |
| 27 more term ends in 2042 · Pro | |||||
10 of 37 patents shown. Soonest term end first, then patent number.
Pro members see all 37.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.